S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
New CBOE “special perk” helps traders target income every weekend (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Recent Reports Are A Wake-Up Call For Investors (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
Recent Reports Are A Wake-Up Call For Investors (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
New CBOE “special perk” helps traders target income every weekend (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Recent Reports Are A Wake-Up Call For Investors (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
Recent Reports Are A Wake-Up Call For Investors (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
New CBOE “special perk” helps traders target income every weekend (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Recent Reports Are A Wake-Up Call For Investors (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
Recent Reports Are A Wake-Up Call For Investors (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary
S&P 500   4,585.59
DOW   36,117.38
QQQ   390.43
Forward dividend yield: What it is and how to use it 
New CBOE “special perk” helps traders target income every weekend (Ad)
What are consumer staples stocks?
Healthcare sector: Overview and keys to investing
Recent Reports Are A Wake-Up Call For Investors (Ad)
Is Amazon a blue chip stock?
How to find penny stocks to invest and trade 
Recent Reports Are A Wake-Up Call For Investors (Ad)
How to invest in GTE technology: A guide 
Consumer staples vs. consumer discretionary

Anika Therapeutics Stock Price, News & Analysis (NASDAQ:ANIK)

$22.48
+0.51 (+2.32%)
(As of 12/7/2023 ET)
Compare
Today's Range
$21.84
$22.59
50-Day Range
$18.47
$22.75
52-Week Range
$16.54
$32.33
Volume
68,194 shs
Average Volume
118,644 shs
Market Capitalization
$329.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.50

Anika Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
13.4% Upside
$25.50 Price Target
Short Interest
Healthy
3.44% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.70
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.45) to ($0.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

549th out of 960 stocks

Medical Instruments & Supplies Industry

6th out of 8 stocks


ANIK stock logo

About Anika Therapeutics Stock (NASDAQ:ANIK)

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and bone preserving joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief; and Hyvisc, a molecular weight injectable HA veterinary product. The company's joint preservation and restoration product family comprises 150 bone preserving joint technology products, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and orthopedic regenerative solutions, including Hyalofast and Tactoset. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including adhesion barrier, advanced wound care, ear, nose, and throat products, as well as ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

ANIK Stock Price History

ANIK Stock News Headlines

The Battery Metal Nobody Told You About
According to McKinsey and Company, the battery storage market is growing rapidly, especially with the transition to clean, renewable energy. Lithium-ion batteries still grab most of the headlines. But analysts now call safe and long-lasting batteries made with vanadium "the future of battery tech."
Q3 2023 Anika Therapeutics Inc Earnings Call
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Q2 2023 Anika Therapeutics Inc Earnings Call
Hemostatic Agents Market Research | 2023-2030
See More Headlines
Receive ANIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
12/07/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/04/2024

Industry, Sector and Symbol

Industry
Medical Instruments & Supplies
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:ANIK
CUSIP
03525510
Employees
345
Year Founded
1992

Price Target and Rating

Average Stock Price Target
$25.50
High Stock Price Target
$28.00
Low Stock Price Target
$23.00
Potential Upside/Downside
+13.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-14,860,000.00
Pretax Margin
-17.46%

Debt

Sales & Book Value

Annual Sales
$163.31 million
Cash Flow
$0.50 per share
Book Value
$19.55 per share

Miscellaneous

Free Float
13,785,000
Market Cap
$329.13 million
Optionable
Optionable
Beta
0.73

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Cheryl Renee Blanchard Ph.D. (Age 59)
    President, CEO & Director
    Comp: $1.31M
  • Mr. Michael L. LevitzMr. Michael L. Levitz (Age 49)
    Executive VP, CFO & Treasurer
    Comp: $710.6k
  • Mr. David Colleran J.D. (Age 51)
    Executive VP, General Counsel & Corporate Secretary
    Comp: $664.54k
  • Ms. Anne Nunes (Age 54)
    Senior VP & COO
  • Mr. Ian W. McLeod
    VP & Chief Accounting Officer
  • Mr. Mark Namaroff (Age 60)
    Executive Director of Investor Relations & Corporate Communications
  • Mr. James Chase
    Senior Vice President of International Sales & Marketing
  • Mr. Ben Joseph
    Vice President of Commercial & Corporate Development
  • Ms. Lisa Funiciello
    Vice President of Human Resources














ANIK Stock Analysis - Frequently Asked Questions

Should I buy or sell Anika Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ANIK shares.
View ANIK analyst ratings
or view top-rated stocks.

What is Anika Therapeutics' stock price target for 2024?

2 equities research analysts have issued 12-month target prices for Anika Therapeutics' shares. Their ANIK share price targets range from $23.00 to $28.00. On average, they anticipate the company's share price to reach $25.50 in the next twelve months. This suggests a possible upside of 13.4% from the stock's current price.
View analysts price targets for ANIK
or view top-rated stocks among Wall Street analysts.

How have ANIK shares performed in 2023?

Anika Therapeutics' stock was trading at $29.60 at the beginning of 2023. Since then, ANIK stock has decreased by 24.1% and is now trading at $22.48.
View the best growth stocks for 2023 here
.

Are investors shorting Anika Therapeutics?

Anika Therapeutics saw a drop in short interest in the month of November. As of November 15th, there was short interest totaling 489,100 shares, a drop of 7.5% from the October 31st total of 528,900 shares. Based on an average daily trading volume, of 203,300 shares, the short-interest ratio is presently 2.4 days. Currently, 3.4% of the shares of the stock are sold short.
View Anika Therapeutics' Short Interest
.

When is Anika Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our ANIK earnings forecast
.

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics, Inc. (NASDAQ:ANIK) issued its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.26. The biotechnology company had revenue of $39.54 million for the quarter, compared to analyst estimates of $36.45 million. Anika Therapeutics had a negative net margin of 15.05% and a negative trailing twelve-month return on equity of 3.32%. During the same period in the prior year, the business earned ($0.45) EPS.

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Trigran Investments Inc. (15.14%), Acadian Asset Management LLC (2.30%), Ameriprise Financial Inc. (1.67%), Northern Trust Corp (1.00%), Charles Schwab Investment Management Inc. (0.78%) and Capital Management Corp VA (0.58%). Insiders that own company stock include Cheryl R Blanchard, David Colleran, Jeffery S Thompson, John B Henneman III, Michael L Levitz and Raymond J Land.
View institutional ownership trends
.

How do I buy shares of Anika Therapeutics?

Shares of ANIK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ANIK) was last updated on 12/8/2023 by MarketBeat.com Staff

My Account -